Everything we’d tell you
on the call, written down.

Your gut already makes two hormones after you eat: GLP-1 and GIP. They tell your brain you’re full and tell your stomach to slow down. Tirzepatide works on both receptors at once, which is why it’s described as dual-action.

• GLP-1 side: signals fullness to the brain, slows how fast food leaves your stomach, and helps steady blood sugar.
• GIP side: acts on fat cells and supports insulin sensitivity, and appears to amplify the GLP-1 effect.
• Why food noise quiets: the constant mental chatter about food is driven by hormone signalling, not willpower. Turn the signal back up and the chatter drops.
• Why you feel full sooner: slower gastric emptying means smaller portions genuinely satisfy you, instead of you white-knuckling through a smaller plate.
• What it doesn’t do: it doesn’t choose your protein, protect your muscle, or build the habits that hold after you taper. That part is the plan.

The medication creates the conditions. What you do around it decides the outcome. These six come first, before anything else — and they’re the ones our dietitians build every plan on.

• Protein first, every day. Roughly 1 gram per pound of your goal weight, spread across meals. This is the single highest-leverage habit on a GLP-1.
• Strength train three times a week. Resistance work is the proven way to hold onto muscle while fat comes off. Cardio alone won’t do it.
• Hydrate deliberately. Around 80–100 oz of water daily. Dehydration makes every side effect worse and stalls progress.
• Eat small and often. Two or three smaller meals beat one large one. Big meals are the most common nausea trigger.
• Cover the gaps. Eating less means fewer nutrients. A multivitamin, magnesium, B12 and vitamin D are the usual bases, and creatine helps with muscle.
• Don’t tough it out alone. Side effects are manageable, and there’s usually something simple that helps. Tell your provider early rather than quitting in week three.

Nutrition, movement and hydration are our lane as dietitians. Anything about your dose, a missed injection, or symptoms you’re having right now goes to your prescribing physician.

Retatrutide adds a third receptor to the picture, which means appetite drops and energy expenditure rises at the same time. The nutrition fundamentals matter more here, not less — because it’s easier to under-eat without noticing.

• Protein target holds. Roughly 1 gram per pound of goal weight. Shakes count when solid food feels like too much.
• Resistance training, three times a week. Without it, a meaningful share of what you lose can come from lean tissue.
• Electrolytes, not just water. Sodium, potassium and magnesium matter especially in the first couple of months.
• Don’t skip meals. Even with no appetite. Consistent intake is what prevents muscle loss and fatigue.
• Give it time. The full effect builds over weeks. Judging it too early is the most common mistake.

Retatrutide is investigational and has not been approved by the FDA. Where we make it available, it is compounded by a licensed U.S. pharmacy under physician oversight, for appropriate candidates only.

Semaglutide works on one receptor. Tirzepatide works on two. Retatrutide works on three — GLP-1, GIP, and glucagon. That third one is the whole story.

• GLP-1: appetite, fullness, slower digestion, steadier blood sugar.
• GIP: insulin sensitivity and a direct effect on fat cells.
• Glucagon: the new part — it raises energy expenditure and mobilises stored fat, so your body uses more fuel at rest rather than only taking less in.
• Why that combination is interesting: eating less and burning more usually pull against each other. A triple agonist is an attempt to do both at once.
• Where it stands: retatrutide is investigational and has not been approved by the FDA. The published data is early and promising, and it is not the same thing as an approved medicine.

This guide is education, not a recommendation. Whether retatrutide is appropriate for you is a decision for a licensed physician who has reviewed your full history.

All three sit in the same family, but they work through a different number of hormone pathways, and that difference is what most of the comparison comes down to.

• Semaglutide — one pathway. GLP-1 only. The longest real-world track record and the most name recognition.
• Tirzepatide — two pathways. GLP-1 plus GIP. This is what our 90-Day program uses.
• Retatrutide — three pathways. Adds glucagon. Investigational and not FDA-approved.
• The honest part: the best medication is the one that fits your history, your response, and your tolerance. That’s a physician’s call after reviewing your intake, not something a comparison table decides.